Physician profile
Gaston M Ponte
NPI 1518168293
$905,924.75
in general payments reported to CMS, 2019-2025
48 companies · $140K in 2025
The $140K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128K · 2020: $115K · 2021: $146K · 2022: $166K · 2023: $112K · 2024: $99K · 2025: $140K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $305K · Travel and Lodging: $12K · Food and Beverage: $11K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $9,800 · Consulting Fee: $6,025 · Honoraria: $5,776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $305,012.69 |
| Travel and Lodging | $12,237.19 |
| Food and Beverage | $11,292.34 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $9,800.00 |
| Consulting Fee | $6,025.00 |
| Honoraria | $5,776.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $371,730.30 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $343,970.62 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $99,893.95 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67,897.44 | 2019-2024 | Jardiance |
| Corcept Therapeutics | $9,762.98 | 2020-2024 | Korlym |
| Dexcom, INC. | $3,568.77 | 2019-2023 | Dexcom G6 Transmitter |
| Medtronic, INC. | $1,637.68 | 2021-2025 | Minimed 780g, Minimed 770g |
| Sanofi-Aventis U.S. LLC | $993.90 | 2019-2023 | |
| Amgen INC. | $725.27 | 2019-2025 | Tepezza, Evenity, Prolia |
| Tandem Diabetes Care, INC. | $592.76 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals Lp | $572.78 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $408.41 | 2021-2024 | Recorlev |
| Ibsa Pharma INC. | $367.42 | 2019-2022 | |
| Beta Bionics, INC. | $350.99 | 2024 | Ilet Bionic Pancreas |
| Valeritas, INC. | $328.91 | 2019 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gaston Ponte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.